Vaccinations can be safe and effective during dupilumab treatment, according to the consensus of a panel published in Annals of Allergy, Asthma & Immunology.
But these vaccinations should proceed only after physicians and patients have shared in the decision-making, Jay A. Lieberman, MD, associate professor, department of pediatrics, University of Tennessee Health Science Center, and colleagues wrote.
Dupilumab (Dupixent; Regeneron, Sanofi) has been approved for treating a variety of inflammatory diseases, the authors wrote, yet patients in its phase 3 trials were not allowed to receive